NAVB News 1.66 Navidea Biopharmaceuticals Inc. (NAVB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Navidea Biopharmaceuticals Inc. (NAVB) 1.66 $NAVB

Navidea Biopharmaceuticals Provides Progress Updates on Lymphoseek(R) Programs
Business Wire - Thu Apr 17, 4:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today provided updates on several programs and events relating to Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection, including a head-to-head clinical study underway at the University of California, San Diego (UCSD). The UCSD study is comparing the level of discomfort experienced by breast cancer patients after injection of Lymphoseek or radiolabeled sulfur colloid in lymphatic mapping procedures. Navidea also highlighted updates on the European filing for Lymphoseek with the Marketing Authorization Application (MAA) and multiple upcoming medical and scientific presentations. Lymphoseek is a novel, receptor-targeted, small-molecule radiopharmaceutical approved by the U.S. Food and Drug Administration for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc.
PR Newswire - Fri Apr 11, 6:00AM CDT
Navidea Pharmaceuticals, Inc. (NYSEMKT: NAVB), is a biopharmaceutical company that is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Its core product, Lymphoseek, a small-molecule radiopharmaceutical used in lymphatic mapping procedures, helps physician identify and target the lymph nodes that drain from a primary tumor that contain cancer cells.

Navidea Announces Presentation of Study Findings of Manocept(TM) Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting
Business Wire - Thu Apr 10, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept(TM) platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS). The investigators concluded that, based on the results obtained, labeled imaging agents from the CD206-targeting Manocept platform provide potential avenues to enhance diagnosis and staging in this disorder.

Navidea Announces Presentations Highlighting NAV4694 Beta-Amyloid, PET Imaging Agent at the German Society of Nuclear Medicine Congress
Business Wire - Wed Mar 26, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the Department of Nuclear Medicine at University Hospital of Leipzig plan presentations highlighting Navidea's PET imaging agent, NAV4694, at the German Society of Nuclear Medicine Annual Congress in Hannover, Germany, March 26-29, 2014. NAV4694 is an investigational Fluorine-18 labeled beta-amyloid imaging agent currently being evaluated in late stage clinical trials for use as an aid in differential diagnosis and to monitor progression of Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and other forms of neurodegenerative dementia.

Navidea Biopharmaceuticals Provides Update on European Marketing Authorization Application for Lymphoseek(R)
Business Wire - Wed Mar 19, 4:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that today it held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the Committee will continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.

Navidea Biopharmaceuticals Announces Presentation of Lymphoseek(R) Three-Year Recurrence and Survival Outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and Melanoma
Business Wire - Fri Mar 14, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results of a three-year, voluntary follow-up study of Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection conducted in patients who participated in a Phase 3 clinical trial (NEO3-05) of the product. The primary objective of the follow-up study was to determine the regional (i.e., draining lymph node basin) recurrence-free rate (RRFR) after sentinel lymph node biopsy with Lymphoseek. Results of the follow-up study indicated that in patients who were confirmed to be node-negative (N0) after sentinel lymph node biopsy (n=88; 49 breast cancer, 39 melanoma) the RRFR was 98.8% (100% in breast cancer; 97.4% in melanoma) and the disease-specific survival rate (DSSR) was 98.6% (97.8% in breast cancer; 100% in melanoma) at three years. The results, presented by Stephen P. Povoski, MD, of The Ohio State University Wexner Medical Center, will also be highlighted in a Grand Rounds presentation as one of several Lymphoseek presentations at SSO 2014, the 67th Society of Surgical Oncology Annual Cancer Symposium, in Phoenix, Arizona. Lymphoseek is a novel, receptor-targeted, small-molecule radiopharmaceutical approved by the U.S. Food and Drug Administration for use in lymphatic mapping to assist in the localization of lymph nodes draining primary tumor in patients with breast cancer or melanoma

Why Navidea Biopharmaceuticals, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 2:19PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...

Navidea Announces Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Mar 06, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results for the fourth quarter and year ended December 31, 2013.

Navidea Biopharmaceuticals Closes $30 Million Loan with Oxford Finance, LLC
Business Wire - Thu Mar 06, 6:00AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has closed a $30 million non-dilutive loan transaction with Oxford Finance LLC ("Oxford" . The loan funds will be used to support Lymphoseek(R) commercialization activities, advance the Company's clinical pipeline, accelerate certain development programs, repay certain of the Company's existing outstanding indebtedness and provide for other general corporate purposes. Navidea believes the Oxford loan provides enhanced working capital with no balance sheet restrictions or covenants, lowers the interest rate and lengthens the interest-only period on the Company's debt, and augments the Company's financial flexibility at a critical time in its growth.

Navidea Announces Acceptance for Review of an Additional sNDA to Further Expand Lymphoseek(R) Labeling
Business Wire - Wed Mar 05, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review an additional Supplemental New Drug Application (sNDA) for the proposed expanded label for Lymphoseek(R) (technetium 99m tilmanocept) Injection to support broader and more flexible use in imaging and lymphatic mapping procedures, including lymphoscintigraphy and other optimization capabilities. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target review date for the second Lymphoseek sNDA of October 16, 2014.

Research and Markets: Concise Analysis of the International and Chinese Airbag Industry
Business Wire - Tue Mar 04, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zs4g8r/global_and) has announced the addition of the "Concise Analysis of the International and Chinese Airbag Industry" report to their offering.

Navidea Biopharmaceuticals to Announce Fourth Quarter and Full-Year 2013 Financial Results on Thursday, March 6, 2014
Business Wire - Mon Mar 03, 1:18PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the fourth quarter and full-year 2013, on Thursday, March 6, 2014 before the market opens. Company management will host a conference call and slide presentation via webcast, also on March 6, 2014, at 8:30 a.m. ET to discuss results and corporate developments.

Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Wed Feb 19, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Perry A. Karsen has been appointed to the Navidea Board of Directors. Mr. Karsen has more than 30 years of experience in the pharmaceutical and biotechnology industries, including key roles at Celgene Corporation. His appointment increases the number of directors on Navidea's Board to seven.

Navidea Announces Priority Review for the sNDA to Expand Lymphoseek(R) Labeling for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer
Business Wire - Tue Feb 18, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) and granted a Priority Review for the expanded use of Lymphoseek(R) (technetium 99m tilmanocept) Injection indicated for sentinel lymph node (SLN) detection in patients with head and neck cancer. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target review date for the Lymphoseek sNDA of June 16, 2014. The FDA grants priority review status to drug applications that may offer a significant improvement in treatment over existing options. Lymphoseek is currently approved for use in lymphatic mapping procedures performed to aid in the diagnostic evaluation of lymph nodes draining a primary tumor in patients with breast cancer and melanoma.

Navidea Biopharmaceuticals Announces the Presentation of Manocept(TM) Data at Keystone Symposia for Molecular Cell Biology of Macrophages in Human Disease
Business Wire - Thu Feb 13, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced data utilizing compounds from the Company's Manocept(TM) platform in models of rheumatoid arthritis are being presented by Thomas Rosol, DVM, PhD, DACVP from The Ohio State University at a Keystone Symposia on Molecular Cell Biology of Macrophages in Human Disease held, February 9-14 in Santa Fe, NM.

Navidea Biopharmaceuticals Announces Positive Initial Results in Single-Center Cohort from Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)
Business Wire - Thu Feb 06, 8:15AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company's investigational beta-amyloid imaging agent, NAV4694, produced highly differentiated images in the first cohort of subjects enrolled in the Company's Phase 2b positron emission tomography (PET) imaging study of subjects with Mild Cognitive Impairment (MCI). The subjects were enrolled and evaluated at the Alzheimer's Disease Center at Quincy Medical Center, Quincy, MA. The results indicate that NAV4694 produced high-quality diagnostic images that segregated MCI subjects into two discrete groups, either amyloid-positive or amyloid-negative.

Navidea Biopharmaceuticals to Present at the 16th Annual BIO CEO and Investor Conference
Business Wire - Tue Feb 04, 11:32AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, VMD PhD, Navidea Chief Executive Officer, will present at the 16th Annual BIO CEO and Investor Conference held at the Waldorf Astoria in New York City, NY on February 10-11, 2014. Dr. Pykett will provide an update on the Company and its commercial and development programs on Monday, February 10, 2014 at 1:30 pm ET.

Navidea Biopharmaceuticals to Present at 2014 Biotech Showcase(TM) Conference
Business Wire - Tue Jan 07, 1:58PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, VMD PhD, Navidea Chief Executive Officer, and other members of Navidea management will participate in the 2014 Biotech Showcase Conference from January 13-15, 2014 held at the Parc 55 Wyndham-Union Square in San Francisco, CA. Dr. Pykett will provide an update of the Company and its commercial and development programs on Monday, January 13, 2014 at 11:00 AM PST in the Powell Room.

Navidea Biopharmaceuticals Expands Lymphoseek(R) Global Commercialization Efforts
Business Wire - Tue Jan 07, 6:29AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd. (GMST), a leading in-country distributor of nuclear medicine and diagnostic imaging products. The contract with GMST follows an agreement recently signed for Lymphoseek distribution in Canada, affording local access to that market as well. Navidea has also recently commenced shipment of Lymphoseek to select medical centers in the Middle East. These market expansion activities build on the growth of Lymphoseek sales in the United States, which continue the positive trends recently reported at the Company's Analyst Science Day on December 5, 2013.

European Medicines Agency (EMA) Continues Marketing Authorization Application (MAA) Review for Lymphoseek(R)
Business Wire - Thu Dec 19, 5:00PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the European Medicines Agency (EMA) has provided updated Day 180 feedback and has elected to continue the assessment of the Marketing Authorization Application (MAA) for Lymphoseek(R) (technetium 99m tilmanocept) Injection. The updated Day 180 feedback was limited to supplemental product specification data and the NEO3-06 Phase 3 study in Head and Neck Cancer, which was submitted later in the MAA review process at Day 120, leaving less time for evaluation of these new data. The MAA review clock will continue to be stopped at Day 180 to await Navidea's responses to the updated EMA feedback. During this time, the MAA remains active and Navidea will continue its ongoing process of interacting with the EMA.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 55

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Regulatory T-Cells Market Growth Driven by New Therapies

Updated Category News Views 217

Insights into the Regulatory T-Cells Market Growth The landscape of the Treg therapy market is rapidly evolving as companies globally actively develop innovative regulatory T-cell therapies to treat various critical conditions. These include systemic lupus erythematosus (SLE), lupus nephritis, atopic dermatitis, rheumatoid arthritis, psoriasis, progressive multiple...

Continue Reading
Natural Grocers Unveils Autumnfest Super Savings Event

Updated Category News Views 67

Natural Grocers Introduces Autumnfest Savings Event As the autumn leaves begin to fall, Natural Grocers invites shoppers to revel in the festivities of the season with their exciting Autumnfest Savings Event. This annual celebration promises customers an incredible opportunity to enjoy significant discounts, free samples, and delightful seasonal recipes. With savings of...

Continue Reading
Anthem Blue Cross Commits $10 Million for Wildfire Relief

Updated Category News Views 270

Anthem Blue Cross Generously Assists Communities Affected by Wildfires For over eight decades, Anthem Blue Cross has maintained a strong presence in California, prioritizing the health and well-being of its residents. Our focus has always been on putting people first, as we acknowledge the struggles that come with disasters that can significantly impact the lives of our...

Continue Reading
Corporate Legal Departments Face Major Workforce Challenges

Updated Category News Views 179

Corporate Legal Departments Face Major Workforce Challenges In the evolving landscape of corporate legal departments, a significant wave of attrition is looming as in-house attorneys express a desire to seek better opportunities. The increase in workloads, coupled with concerns about artificial intelligence and limited career advancement prospects, has prompted many legal...

Continue Reading
Currax Achieves FDA Approval for Enhanced CONTRAVE Supply Chain

Updated Category News Views 411

Currax Expands Manufacturing Capabilities for CONTRAVE Currax Pharmaceuticals LLC, a focused specialty pharmaceutical company, recently announced a significant milestone in its operations. The U.S. Food and Drug Administration (FDA) has granted approval for a second manufacturing facility dedicated to the production of CONTRAVE (naltrexone HCl/bupropion HCl), a leading...

Continue Reading